AbbreviationsACTAsthma Control TestDSPDisease Specific ProgramEDemergency departmentFEV1forced expiratory volume in 1 sGINAGlobal Initiative for AsthmaICSinhaled corticosteroidLTRAleukotriene receptor antagonistSOBshortness of breathTCMtraditional Chinese medicineINTRODUCTIONAsthma is a common, chronic respiratory disease estimated to affect 1.0–18.0% of the population depending on the country. The 2002 prevalence estimates of 3.0–6.0% for Asia‐Pacific nations are lower compared with Western countries, although prevalence in Asia appears to be on the rise. This increase has been attributed to environmental exposures, with children and the elderly at highest risk.Thirty million people in China are affected by asthma. A household survey of more than 180 000 individuals 14 years or older residing in eight provinces of China revealed an overall asthma prevalence of 1.2%, while other studies report a prevalence of 1.1% across all age groups. Prevalence is higher in urban areas at 1.4% versus 0.9% for rural locations. Crucially and consistent with trends in other Asia‐Pacific countries, asthma prevalence in China appears to be increasing.Treatment goals include optimal symptom control, maintenance of normal activity levels and reductions in exacerbations and fixed airflow limitations, with minimal side effects. Pharmacological treatment options are guided by severity. Mild asthma is asthma that is well controlled with Step 1 or Step 2 treatment
Respirology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera